Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals

Immunocon, MabGalaxy Forge Full-Chain AI Antibody R&D Network for Bispecific Drug Development

Fineline Cube Jul 7, 2026
Company Deals

Vertex Pharmaceuticals to Acquire Crinetics for $10B, Adding PALSONIFY and Atumelnant to Endocrine Portfolio

Fineline Cube Jul 7, 2026
Company Deals

Hainan Shuangcheng Pharmaceutical Secures $10M US Licensing Deal for SC-C141 R&D Project

Fineline Cube Jul 7, 2026
Company Deals

CStone Pharmaceuticals Partners with Arrotex for Sugemalimab Commercialization Across Australia and New Zealand

Fineline Cube Jul 7, 2026
Company Deals

Serapha Bio Secures $2B+ Base Editing Therapy Deal for AATD with YolTech and Completes $230M Merger

Fineline Cube Jul 7, 2026
Drug Policy / Regulatory

China NMPA Launches PIONEER Program to Accelerate NAMs Adoption in Drug Development

Fineline Cube Jul 7, 2026
Drug Policy / Regulatory

China NMPA Launches PIONEER Program to Accelerate NAMs Adoption in Drug Development

Fineline Cube Jul 7, 2026
Company Drug

Sino Biopharmaceutical Submits China Marketing Application for World’s First Intra-Incisional Long-Acting Ropivacaine Analgesic

Fineline Cube Jul 6, 2026
Company Deals

Eli Lilly Acquires Point Biopharma to Enhance Oncology Portfolio

Fineline Cube Oct 8, 2023

Eli Lilly (NYSE: LLY) announced last week its agreement to acquire radiopharmaceutical company Point Biopharma...

Company Drug

Sanofi’s Nexviazyme Approved in China as Enzyme Replacement Therapy for Pompe Disease

Fineline Cube Oct 8, 2023

Sanofi’s (NASDAQ: SNY) next-generation enzyme replacement therapy (ERT), Nexviazyme (avalglucosidase alfa), has received marketing approval...

Policy / Regulatory

NMPA and NHC Tighten Regulations on Etomidate and Modafinil

Fineline Cube Oct 8, 2023

The National Medical Products Administration (NMPA) and the National Health Commission (NHC) have jointly issued...

Company Deals

Hangzhou HealSun Biopharm Secures RMB 200 Million in Series B+ Financing

Fineline Cube Oct 8, 2023

Hangzhou HealSun Biopharm Co., Ltd., a Chinese contract research organization (CRO) and contract development and...

Company

Viatris to Divest Women’s Health and API Businesses, Offloading 12 Factories and 6,000 Employees

Fineline Cube Oct 8, 2023

US-based Viatris Inc. (NASDAQ: VTRS) is set to divest its women’s health business, API operations...

Company Deals

Janssen and Sanofi Partner for Development of First-in-Class E. coli Vaccine

Fineline Cube Oct 7, 2023

The Janssen unit of Johnson & Johnson (J&J; NYSE: JNJ) has entered into a strategic...

Company Drug

Takeda Initiates Global Withdrawal of Exkivity Following Phase III Trial Results

Fineline Cube Oct 7, 2023

Japan-based Takeda (TYO: 4502) has announced the voluntary global withdrawal of its tyrosine kinase inhibitor...

Company Deals

Kyowa Hakko Kirin to Acquire Orchard Therapeutics for $477.6 Million

Fineline Cube Oct 7, 2023

Japan-based Kyowa Hakko Kirin is poised to acquire UK-headquartered Orchard Therapeutics plc for a total...

Company Deals

PharmaEssentia Announces Licensing Agreement with WuXi Biologics for Antibody Development

Fineline Cube Oct 7, 2023

Taiwan-based PharmaEssentia Corporation (TPE: 6446, FRA: 8Z1) has entered into a licensing agreement with China’s...

Company Deals

Boehringer Ingelheim Collaborates with Zeiss Medical Technology on Retinal Disease Detection

Fineline Cube Oct 7, 2023

Germany’s Boehringer Ingelheim (BI) has entered into a collaboration agreement with fellow German firm Zeiss...

Policy / Regulatory

Guangdong Medicine Exchange Announces Volume-Based Procurement for Medical Devices

Fineline Cube Oct 7, 2023

The Guangdong Medicine Exchange has issued three notifications regarding the volume-based procurement (VBP) of medical...

Deals Medical Device

Cardinal Health Acquires MedAlliance for $1.135 Billion to Enhance Vascular Intervention Portfolio

Fineline Cube Oct 7, 2023

US-based Cardinal Health (NYSE: CAH) has announced the acquisition of Swiss firm MedAlliance for a...

Company Deals

Hong Kong Government Partners with AstraZeneca, Tigermed, and Simcere to Boost Innovation

Fineline Cube Oct 7, 2023

The government of the Hong Kong Special Administrative Region has entered into significant partnership agreements...

Company Drug

Everest Medicines and Calliditas Present New Data on Nefecon for IgA Nephropathy

Fineline Cube Oct 7, 2023

Everest Medicines (HKG: 1952), in partnership with Calliditas Therapeutics AB (Nasdaq: CALT), recently presented new...

Company Drug

Zhaoke Ophthalmology Completes Patient Enrollment for Phase III Trials of TAB014 and Epinastine

Fineline Cube Oct 7, 2023

Zhaoke Ophthalmology Ltd (HKG: 6622), a former subsidiary of Lee’s Pharmaceutical Holdings Ltd (HKG: 0950),...

Company Drug

Amicus Therapeutics Secures FDA Approval for Pombiliti and Opfolda Combination Therapy

Fineline Cube Oct 7, 2023

Amicus Therapeutics (NASDAQ: FOLD), headquartered in the United States, has announced that it has received...

Company Deals

Vela Diagnostics Partners with SRL Inc. to Expand Molecular Diagnostics in Japan

Fineline Cube Oct 7, 2023

Singapore-based Vela Diagnostics, a global leader in integrated molecular solutions for diagnosing infectious diseases and...

Company Drug

Transcenta Secures FDA Approval for Phase III Trial of Osemitamab

Fineline Cube Oct 7, 2023

China-based Transcenta Holding Ltd (HKG: 6628) has announced that it has received approval from the...

Policy / Regulatory

Shanghai Boosts Community Healthcare with Enhanced Reimbursement and Services

Fineline Cube Sep 28, 2023

Shanghai’s healthcare security administration has announced a comprehensive set of measures aimed at enhancing community...

Company Deals

Novo Nordisk and Evotec Launch LAB eN² to Accelerate Drug Discovery for Rare Diseases

Fineline Cube Sep 28, 2023

Global healthcare company Novo Nordisk (NYSE: NVO) and drug discovery alliance Evotec (NASDAQ: EVO) have...

Posts pagination

1 … 490 491 492 … 691

Recent updates

  • China NMPA Launches PIONEER Program to Accelerate NAMs Adoption in Drug Development
  • Immunocon, MabGalaxy Forge Full-Chain AI Antibody R&D Network for Bispecific Drug Development
  • Vertex Pharmaceuticals to Acquire Crinetics for $10B, Adding PALSONIFY and Atumelnant to Endocrine Portfolio
  • Hainan Shuangcheng Pharmaceutical Secures $10M US Licensing Deal for SC-C141 R&D Project
  • CStone Pharmaceuticals Partners with Arrotex for Sugemalimab Commercialization Across Australia and New Zealand
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Drug Policy / Regulatory

China NMPA Launches PIONEER Program to Accelerate NAMs Adoption in Drug Development

Company Deals

Immunocon, MabGalaxy Forge Full-Chain AI Antibody R&D Network for Bispecific Drug Development

Company Deals

Vertex Pharmaceuticals to Acquire Crinetics for $10B, Adding PALSONIFY and Atumelnant to Endocrine Portfolio

Company Deals

Hainan Shuangcheng Pharmaceutical Secures $10M US Licensing Deal for SC-C141 R&D Project

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.